TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has provided an update.
Fusen Pharmaceutical Co., Ltd. announced that its subsidiary, Jiaheng Pharmaceutical Technology, has received approval from the National Medical Products Administration of the PRC to market ‘Measartan Potassium Tablets’ for treating primary hypertension. This product, containing azilsartan medoxomil potassium, enhances the company’s portfolio in the blood circulatory system field, offering a new treatment option for hypertension with significant and stable effects, and aligns with the company’s strategy to strengthen its market position in the antihypertensive drug sector.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. The company, along with its subsidiaries, develops and markets medical products, with a particular emphasis on treatments for the blood circulatory system.
Average Trading Volume: 2,542,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$602.9M
For detailed information about 1652 stock, go to TipRanks’ Stock Analysis page.